About Bloomage Biotechnology Corporation Limited Company

The company is a well-known biotechnology company and biomaterials company. Driven by synthetic biotechnology, the company is committed to continuously improving the quality of life, extending the length of life, and bringing a healthy, beautiful and happy life experience to humans. The company is a world-renowned biotechnology company driven by synthetic biotechnology innovation and a platform company for the entire biomaterials industry chain. It has two major technology platforms for microbial fermentation and crosslinking, as well as six major R&D platforms, including a pilot transformation platform, a formulation process R&D platform, a synthetic biology R&D platform, and an application mechanism research and development platform. The company's main products are raw materials, medical terminal products in the field of hyaluronic acid biomedical materials, “BIOHYALUX (BIOHYALUX),” “QUADHA (MEDRESS),” “BM Skin Activity” (Bio-meso), “BLOOMCARE (BLOOMCARE),” functional foods, etc. The company has successively been recognized as a research platform such as the National Enterprise Technology Center, the State Drug Administration's Key Laboratory for Quality Control of Cosmetic Ingredients (joint declaration), the Shandong Key Laboratory for Synthetic Biology of Bioactive Substances (planned), etc., and has received national and provincial honors such as the National Manufacturing Industry Single Champion Demonstration Enterprise, the Shandong Provincial Science and Technology Progress Award, and the Shandong Governor's Quality Award. In 2022, the company's scientific and technological innovation capabilities were recognized by the Shandong Academician Workstation and the Tianjin Key Laboratory's scientific research platform, awarded the National Intellectual Property Advantage Enterprise, and won the Grand Prize of the China Chamber of Commerce. In 2023, the company's scientific and technological innovation capabilities were recognized again, and the Hainan Key Laboratory for Regenerative Medicine Technology and Material Transformation was officially unveiled, and it participated in the joint construction of the National Synthetic Biotechnology Innovation Center and the National Biomantry Industry Innovation Center.